|
|
 |
Incidence
in Patients Receiving NRTIs
| •
|
Case
series of adults receiving NRTI with _lactate and GI symptoms
and/or unexplained _ALT
|
| •
|
Relative
risk for various ART regimens compared to ZDV/3TC was estimated |
| •
|
33
patients met case definition during study period (7/98 and 5/00)
|
| •
|
Incidence
rate among 1611 patients for any NRTI regimen was 14.5 (95%
CI: 10.0-20.3) cases/1000 person-years
|
•
Lonergan and colleagues have been studying symptomatic hyperlactatemia
in a case series of adults receiving NRTIs.1 They are defined as having
an increased lactate level associated with gastrointestinal symptoms
and/or unexplained ALT levels.
• After identifying these cases, the researchers looked at their
therapy as well as the relative risk of developing symptomatic hyperlactatemia
compared to patients who were on zidovudine and 3TC.
• A total of 33 out of 1,611 patients met the case definition
between 1998 and 2000.
• The overall incidence rate for any NRTI regimen was 14.5 cases
per 1000 person-years.
Reference:
1. Longergan JT, Havlir D, Behling C et al. Incidence and outcome
of hyperlactatemia associated with clinical manifestations in HIV-infected
adults receiving NRTI-containing regimens. Program and abstracts of
the 8th Conference on Retroviruses and Opportunistic Infections, Chicago,
IL; February 4-8, 2001. Abstract 624.
|
|
|
|
